Leadership of the Fox Chase Cancer Center is under the direction of its President and Chief Executive Officer, Michael V. Seiden, M.D., Ph.D.;the Deputy Director (DD) and Chief Scientific Officer (CSO),Jonathan Chernoff, M.D., Ph.D.;the Associate Director for Academics (AD-A) and Chief Academic Officer (CAO), J. Robert Beck M.D.;the Associate Director for Networks (AD-N) and Chief Network Officer (CNO), Paul Engstrom, M.D.;and the Associate Director for Clinical Research (AD-CR), Massimo Cristofanilli, M.D, (see Cancer Center Organizational chart on the cover of this section). Seiden has complete authority over all activities of the Center including faculty appointments. Center space and institutional monies. He reports to the Board of Directors. The DD is responsible for the Center's Research Programs, Shared Resources and Research Administration. The AD-A manages the faculty appointment and promotion process, training programs, mentoring. Institutional Review Board, and extramural relationships. The AD-N is responsible for disseminating best practices and working with the Center's extensive network of affiliates. The AD-CR has responsibility for the Protocol Office and clinical research management, including the Research Review Committee. This CCSG-funded Cancer Center leadership group is a subset of Fox Chase Cancer Center's Senior Leadership Council (SLC), which meets weekly to direct all activities of the Center. Included in the SLC are the Chief Operating Officer, Chief Financial Officer, Chief Development Officer, and the Senior Vice President for Business Development and Clinical Operations. The five Cancer Center leaders establish overall research priorities, foster the continued integration of scientific and medical programs, discuss and set recruiting priorities, create senior level search committees, review and approve faculty promotions, and discuss current issues facing Fox Chase Cancer Center and its scientific faculty and staff. In addition, Seiden meets with the DD and AD-A at least weekly (usually daily). The team also makes decisions concerning optimal use of CCSG resources. Examples include reorganizing the Research Programs and Shared Resources, recruiting senior leaders {e.g., Cristofanilli), and empowering Program and Resource leaders. Senior Leadership has recruited 21 faculty since Seiden's assuming the Presidency in 2007.

Public Health Relevance

The Senior Leadership of the Cancer Center is responsible for the organization and administration of the Center and the CCSG. As such the composition, function and effectiveness of the Senior Leadership has immense relevance to the CCSG as a whole.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475329
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$1,851,077
Indirect Cost
$1,670,117
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1280 publications